Article Text

other Versions

PDF
Decreased BAFF-R on peripheral lymphocytes associated with increased disease activity in primary Sjögren’s syndrome and systemic lupus erythematosus
  1. Jérémie Sellam
  1. Bicêtre Hospital, INSERM U802, France
    1. Corinne Miceli-Richard
    1. Bicêtre Hospital, INSERM U802, France
      1. Jacques Eric Gottenberg
      1. Bicêtre Hospital, INSERM U802, France
        1. Marc Ittah
        1. Bicêtre Hospital, INSERM U802, France
          1. Frédéric Lavie
          1. Bicêtre Hospital, INSERM U802, France
            1. Christine Lacabaratz
            1. Bicêtre Hospital, INSERM U802, France
              1. Nicolas Gestermann
              1. Bicêtre Hospital, INSERM U802, France
                1. Alexis Proust
                1. Bicêtre Hospital, INSERM U802, France
                  1. Olivier Lambotte
                  1. Bicêtre Hospital, INSERM U802, France
                    1. Xavier Mariette (xavier.mariette{at}bct.aphp.fr)
                    1. Bicêtre Hospital, INSERM U802, France

                      Abstract

                      Objective:To analyse B-cell activating factor (BAFF) receptor (BAFF-R) on peripheral lymphocytes from patients with primary Sjögren’s syndrome (pSS) and systemic lupus erythematosus (SLE).

                      Patients and methods:Peripheral blood mononuclear cells from 20 pSS, 19 SLE patients and 15 controls were examined by flow cytometry to investigate BAFF-R mean fluorescence intensity (MFI) on lymphocytes. BAFF-R mRNA level from isolated blood B cells of 9 pSS patients and 8 controls was assessed by real-time quantitative RT- PCR. BAFF serum level was determined by ELISA.

                      Results:In all subjects, BAFF-R was expressed on all naïve CD27- and memory CD27+ B cells and was present on <0.5% of T cells. BAFF-R expression on B cells was significantly decreased in pSS patients as compared with controls (MFI=7.8 vs 10.6, p=0.001) and was intermediate in SLE patients (MFI=9.5). Serum BAFF level was inversely correlated with BAFF-R MFI (p=0.007) but not because of competition between endogenous BAFF (at observed concentrations in patients) and the monoclonal antibody (11C1) detecting BAFF-R. BAFF-R mRNA level did not differ between pSS patients and controls (p=0.48). BAFF-R MFI decreased after overnight culture with rhBAFF (from 32.5 to 25.4, p=0.03). Contrary to serum BAFF level, BAFF-R expression was correlated with extraglandular involvement in pSS and SLE Disease Activity Index.

                      ConclusionsBAFF-R expression is reduced on peripheral B cells of pSS and SLE patients. This downregulation occurs through a post-transcriptional mechanism and could be the consequence of chronic BAFF increase. BAFF-R level on B eclls could be a novel activity bio-marker in autoimmune diseases.

                      • B cell
                      • BAFF
                      • BAFF-R
                      • Sjögren’s syndrome
                      • systemic lupus erythematosus

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.